Illumina (ILMN) and EraGen to Form Strategic Partnership
More News related to ILMN
- Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
- After-Hours Movers 2/4: PWER, OPTR, PTIX, HA, TSYS Higher; PWAV, TTMI, MFLX, SNCR, BMI Lower
- Illumina (ILMN) Tops Q4 EPS by 10c; Guides In-Line
- Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2009
- Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc. (NASDAQ: ILMN) today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.
Under these licensing agreements, EraGen Biosciences will have access to Illumina's BeadXpress platform for the continued development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode-PLx technology. EraGen has proven commercial success with multiplex molecular assays for the infectious disease and genetic disorder markets. Illumina has licensed EraGen's MultiCode-PLx technology for the life sciences, research and clinical markets.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
